Skip to main content
Livermore
Livermore
ZHEN

Superstring Capital Management LP

SEC CIK
0001931118
Latest filing
Aug 14, 2026

Holdings in Q4 2024

Holdings as of Dec 31, 2024, filed Feb 14, 2025. Long positions only; changes compare share counts with Q3 2024.

Institution overview
Positions
38
+11 vs. Q3 2024
Portfolio value
$113.9M
+$2.04M (+1.8%) vs. Q3 2024
Filed
Feb 14, 2025
SEC
Holdings of Superstring Capital Management LP in Q4 2024
SecurityClassSharesValue% of portfolioShare changeActionHistory
ORICOric Pharmaceuticals, Inc.COM1,580,745$12.8M11.2%+631,223+66.5%AddedHistory
TERNTerns Pharmaceuticals, Inc.COM2,020,562$11.2M9.8%+672,016+49.8%AddedHistory
ZLABZai Lab LtdADR403,630$10.6M9.3%−223,302−35.6%ReducedHistory
NVCRNovoCure LtdORD SHS286,970$8.55M7.5%−105,741−26.9%ReducedHistory
BBIOBridgeBio Pharma, Inc.COM262,141$7.19M6.3%+35,457+15.6%AddedHistory
COGTCogent Biosciences, Inc.COM910,865$7.10M6.2%+910,865NewHistory
CYTKCytokinetics IncCOM NEW129,389$6.09M5.3%−86,409−40.0%ReducedHistory
GPCRStructure Therapeutics Inc.SPONSORED ADS216,811$5.88M5.2%−10,236−4.5%ReducedHistory
IDYAIDEAYA Biosciences, Inc.COM227,102$5.84M5.1%+227,102NewHistory
URGNUroGen Pharma Ltd.COM301,206$3.21M2.8%+301,206NewHistory
SMMTSummit Therapeutics Inc.COM164,564$2.94M2.6%+164,564NewHistory
TILInstil Bio, Inc.COM NEW148,017$2.83M2.5%+40,472+37.6%AddedHistory
PTGXProtagonist Therapeutics, IncCOM68,892$2.66M2.3%+68,892NewHistory
INSMINSMED IncCOM PAR $.0135,966$2.48M2.2%+35,966NewHistory
FATEFate Therapeutics IncCOM1,379,556$2.28M2.0%−87,378−6.0%ReducedHistory
LEGNLegend Biotech CorpSPONSORED ADS69,594$2.26M2.0%+9,079+15.0%AddedHistory
TARAProtara Therapeutics, Inc.COM STK360,000$1.90M1.7%+360,000NewHistory
CABACabaletta Bio, Inc.COM822,293$1.87M1.6%+690,498+523.9%AddedHistory
DYNDyne Therapeutics, Inc.COM73,150$1.72M1.5%+73,150NewHistory
SVRASavara IncCOM508,338$1.56M1.4%+308,338+154.2%AddedHistory
TNGXTango Therapeutics, Inc.COM474,955$1.47M1.3%−124,093−20.7%ReducedHistory
KURAKura Oncology, Inc.COM157,959$1.38M1.2%+157,959NewHistory
INCYIncyte CorpCOM18,009$1.24M1.1%+18,009NewHistory
ONCBeOne Medicines Ltd.ADR6,365$1.18M1.0%+6,365NewHistory
VSTMVerastem, Inc.COM NEW209,889$1.09M1.0%+209,889NewHistory
ETNB89bio, Inc.COM132,982$1.04M0.9%−462,221−77.7%ReducedHistory
ZBIOZenas BioPharma, Inc.COM111,605$914.0K0.8%00.0%UnchangedHistory
CAPRCapricor Therapeutics, Inc.COM NEW55,229$762.2K0.7%−282,118−83.6%ReducedHistory
KYTXKyverna Therapeutics, Inc.COM182,177$681.3K0.6%+182,177NewHistory
RZLTRezolute, Inc.COM NEW123,184$603.6K0.5%+123,184NewHistory
IPSCCentury Therapeutics, Inc.COM462,963$467.6K0.4%+462,963NewHistory
ZURAZura Bio LtdCLASS A ORD SHS186,943$467.4K0.4%+30,317+19.4%AddedHistory
EYPTEyePoint, Inc.COM NEW49,375$367.8K0.3%+49,375NewHistory
AXSMAxsome Therapeutics, Inc.COM4,268$361.1K0.3%+4,268NewHistory
MDGLMadrigal Pharmaceuticals, Inc.COM1,129$348.4K0.3%+1,129NewHistory
LXEOLexeo Therapeutics, Inc.COM52,616$346.2K0.3%+52,616NewHistory
CLYMClimb Bio, Inc.COM98,160$176.7K0.2%+64,336+190.2%AddedHistory
Lakeshore Biopharma Co LtdG9845F208ORD SHS NEW30,792$106.2K0.1%+30,792New–

Options (1)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Superstring Capital Management LP in Q4 2024
SecurityClassPutsCalls
ORICOric Pharmaceuticals, Inc.COM–$1.61M

Sold out since Q3 2024 (9)

Positions held at the end of Q3 2024 that are gone from this filing.

Positions of Superstring Capital Management LP sold out since Q3 2024
SecurityClassShares in Q3 2024Value in Q3 2024% of portfolio in Q3 2024History
NKTXNkarta, Inc.COM740,294$3.35M3.0%History
ALLOAllogene Therapeutics, Inc.COM478,115$1.34M1.2%History
SYRESpyre Therapeutics, Inc.COM NEW37,287$1.10M1.0%History
BMEABiomea Fusion, Inc.COM83,554$843.9K0.8%History
TRMLTourmaline Bio, Inc.COM29,104$748.3K0.7%History
CRBPCorbus Pharmaceuticals Holdings, Inc.COM NEW25,401$524.0K0.5%History
IMVTImmunovant, Inc.COM12,447$354.9K0.3%History
CGEMCullinan Therapeutics, Inc.COM20,840$348.9K0.3%History
Ys Biopharma Co LtdG9845F109ORDINARY SHARES307,920$212.2K0.2%–